Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents

- 1 -

- 1 - - 1 - ... 1... 2... 4... 5... 9... 11... 14... 16... 20... 21... 22... 23... 23 - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - ( ) - 10 - - 11 - Pseudomonas aeruginosa Escherichia coli Staphylococcus

50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH

3240 14 8 8 50mg 75mg 13 6 25 1-(1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S 1292.26 5-[(1S,2S)-2-

Acecide_ProductsInformation2010PDF.indd

53-0115-00-4PDF 53-0115-00-4PDF INDEX 1 3 9 11 12 16 21 38 39 40 42 43 44 45 46 47 53-0115-00-4PDF 3 1 Critical Semicritical Noncritical Disinfection Sterilization 53-0115-00-4PDF 2 53-0115-00-4PDF O =

特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書（案）

VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.

感染症学雑誌第80巻第6号

Candida Candida albicans Candida parapsilosis Candida glabrata Candida tropicalis C. albicans C. grabrata C. tropicalis µ Candida guilliermondii µc. parapsilosis µ Candida µcandida C. albicans µ µ µ µ

E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian

Key words: yeast, Etest(R), microdilution method, MIC Table 1 MICs of quality control strains The data shown are the range of MIC performed in triplicate Table 2 Renge of MICs, MIC50s and MIC90s for 81

! 1Munderl P et al. Survival and causes of death, 2 years after Introduction of antiretroviral therapy in Africa. XVI International AIDS Conference, 2006, Abstract THLB0208. 2Walensky RP et al. The

名称未設定-1

Study on Clinical Factors Affecting the Fungal Culture Test - Relevance of Dry Mouth - Yoshiko YAMAMURA, Yukihiro MOMOTA, Hideyuki TAKANO, Koichi KANI, Katsumi MOTEGI, Fumihiro MATSUMOTO, Masayuki AZUMA

DIC vegetation 1 nonbacterial thrombogenic e

2001 2002 Guidelines for the Prevention and Treatment of Infective Endocarditis (JCS 2003) h 1 1 2 3 4 5 6 7 8 9 2 1 2 3 1 2 3 4 1 2 5 1 2 1 G Streptococcus viridans Streptococcus bovis 2 G Streptococcus

untitled

HPM_442_F_TgCHG_1128

3M TM Chlorhexidine Gluconate IV Securement Dressings Tegaderm TM CHG Support CRBSI Prevention TegadermTM CHG Dressing 2w/w% 60% N. Safdar, Intensive Care Med 2004 30 62-7 Guideline Centers for Disease

小動物の皮膚真菌症

Small Animal Dermatomycosis 日 本 大 学 生 物 資 源 科 学 部 獣 医 学 科 獣 医 臨 床 病 理 学 研 究 室 准 教 授 加 納 塁 Rui Kano, Veterinary Pathobiology. (Associate Professor) Nihon University College of Bioresouce Sciences 1. はじめに

日本皮膚科学会雑誌第122巻第2号

J Dermatol Sci Vitam Horm NEnglJMed Lancet J Clin Invest Antitoxid Redox Signal Diabetes Metab Res Rev Diabetes Care Diabet Med Diabetes care Diabetes Care J Foot Ankle Surg Wound Repair Regen Lancet Foot

VOL. 17 NO. 7 CHEMOTHERAPY 1305 1) W. BRumFirr et al. : Clinical and laboratory studies with carbenicillin. Lancet 1: 1289~ 1293, 1967 2) E. T. KNUDSEN et al. : A new semisynthetic penicillin active against

日本化学療法学会雑誌第50巻新薬特集号

micafungin in vitro 3 3 micafungin Candida Aspergillus Candida albicans fluconazole Candida tropicalis, Candida glabrata, Candida krusei Aspergillus 90 MIC90 0. g ml amphotericin B fluconazole itraconazole

第65回日本化学療法学会東日本支部総会 抄録

鍵 76 Clostridioides difficile C. difficile 77 γ γ Mycobacterium avium 78 79 Clostridium difficile Treponema pallidum 80 81 82 in vitro in vitro 83 鍵 Treponema pallidum 84 Chlamydia trachomatis Mycoplasma

untitled

untitled

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 1 24 25 26 27 1 28 1 1 2 2 3 3 k k 1 2 3 k 29 30 31 32 33 () 34 35 36 () 37 () () () 38 39 40 41 42 43 2 2 44 45 46 47 48 49 50 51 52 53 54 55

27 2 17 学 説 試 験 問 題 (B) 80 2 81 81 のうち を 横 線 で 81 とマークすれば 良 い HB 良 い 例 悪 い 例 1 Na + 2 K 3 kg mg/kg AUC. g/hr/m. /hr/kg.. /hr/kg.. /hr/kg.. /hr/kg.. /hr/kg. 4 Na + -K + -ATPase 5 a b c d e a, b a, e b,

日本化学療法学会雑誌第56巻第3号

β Key words Candida albicans albicans Candida C. albicans Candida glabrata Candida krusei albicans Candida C. glabrata C. albicans albicans Candida β in vitro in vivo C. glabrata C. krusei I β γ µ Candida

第82 回日本感染症学会総会学術集会後抄録（I）

β Aspergillus Aspergillus β in vitro in vivo α γ α γδ Streptococcus suis S. suis Chlamydia trachomatis C. trachomatis C. trachomatis C. trachomatis Chlamydia Helicobacter pylori H. pylori H. pylori H.

IF MR 63 2 IF 10 3 IF IF IF A4 9 IF IF IF 11 1 IF IF IF MR IF IF MR Drug Safety Update IF

2009 2 1 872612 IF 1998 9 IODINE M DISINFECTANT SOLUTION 10 10w/v 100mL 10g( 1g) PovidoneIodine 2008 10 15 2008 12 19 2009 1 6 IF 2008 12 IF MR 63 2 IF 10 3 IF IF IF A4 9 IF IF IF 11 1 IF IF IF MR IF IF

obayasshi1118.indd

1 Q A 82% 89% 88% 82% 88% 82%

第十五改正日本薬局方第一追補

316 3 5 7 9 9 9 12 13 14 14 14 23 23 23 24 24 29 29 29 35 37 131 161 173 193 194 198 200 205 3 37 37 37 38 38 38 39 39 40 40 41 42 43 43 45 46 47 48 49 50 51 52 52 53 54 54 54 55 56 58 58 59 60 60 61 61

Table 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains

日本化学療法学会雑誌第58巻第2号

Key words β Candida Table1. MCFGCPAstudygroup Investigator (representative) YoshitsuguMiyazaki NaoyukiMiyashita RyoichiAmitani KenjiOgawa AtsuyukiKurashima ToshiroKiguchi MichiakiMishima YuichiInoue HiroshiSaito

日本皮膚科学会雑誌第119巻第5号

I II 1 dermatophytosis tinea 1 2 3 tinea pedis Trichophyton rubrum 4 tinea manus 5 tinea unguium 2 candidiasis, candidosis 3 malassezia infection 4 sporotrichosis Sporothrix schenckii 5 dematiaceous fungal

Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates

08サーベイ部会報告書v1117

CRBSI20012003 CAUTI20042005 2006 VAP VAP CRBSICAUTI X 2006 pilot study 2007 2008 VAP VAP VAP VAP VAP ICN VAP VAP VAP VAP VAP. VAP 2006 VAP 8 2007 2007 42 VAP 2007 2007 VAP 9 2004 NNIS 2007 2008. VAP 2007

Various function and toxicity of iron Key words 1) Hentze, M. W. et al: Cell, 117, 285-297 (2004) 2) Ganz, T.: Blood, 102, 783-788 (2003) 3) Nemeth, E. et al.: Science, 306, 2090-2093 (2004) 4) Hentze,

Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS BPD CHD 50mg100mg RS20138 RS Respiratory Syncytial Virus RS

RS Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS1998 7020021BPD 200510CHD 50mg100mg2012 812 RS20138 RS Respiratory Syncytial Virus RS 28 12 29 35 6 6BPD24 24CHD 24 24 28 2935 RS 12 6 RS BPD

DocuPrint C5450 ユーザーズガイド

1 2 3 4 5 6 7 8 1 10 1 11 1 12 1 13 1 14 1 15 1 16 17 1 1 18 1 19 1 20 1 21 1 22 1 23 1 24 1 25 1 26 27 1 1 28 1 29 1 30 1 31 1 2 12 13 3 2 10 11 4 9 8 7 6 5 34 24 23 14 15 22 21 20 16 19 18 17 2 35

et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology

37 Recommendations for the Management of Moyamoya Disease A Statement from Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) Research on intractable diseases of the

Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST

Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST 13) Danaeus, A., Johansson, S. G. O., Foucard, T. & Ohman, S.: Clinical and immunogical aspects of food allergy in childhood.

94.7 05.1 1 mm 2 3 1) 2) 3) 4 3- -2-3- -2-..... mm 5 ,,,, (15,000ppm) (15,000ppm) (1,000ppm) (5,000ppm) American Conference of Governmental Industrial Hygienists 3,000 6,000 12,000 18,000 6 g/ml Aspergillus

Fig. 1 Chemical structure of DL-8280

Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.

_02.indd

30, 11-16, 2010 Z Z score Computed tomography ROC analysis 3 CT 1,2 CT 1/3 3 5 CT CT 6 7,8 MCA ASPECTS Alberta Stroke Programme Early CT Score 4 10 CT ASPECTS 50% 9 Z 10 CT Z CT 10 Z Z Z receiver operating

2007　Vol.56　No.6　総説　丸山浩樹

Reprinted from RADIOISOTOPES, Vol.56,.6 June 2007 Japan Radioisotope Association http : //www.jrias.or.jp/ α β α β ε m z α µ µ α m z m z µ µ Curr. Opin. Biotechnol J. Proteome Res Rapid Commun. Mass

Complex sleep apnea syndrome and sleep disordered breathing in patients with cardiovascular disease V o l. 4 1 N o. 3 ( 2 0 0 9 ) V o l. 4 1 N o. 3 ( 2 0 0 9 ) V o l. 4 1 N o. 3 ( 2 0 0 9 ) Sleep J Clin

37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate

37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5

SBP hospitalist network.key

1 Treatment and Prophylaxis of Spontaneous Bacterial Peritonitis (1); (2), (3). (1) (2) (3) :, :, 2 Clinical Question 1 72...,.,,.,... 3. CT..,. 4? SBP? SBP. 5 Clinical Question SBP? SBP,? 6 SBP (Spontaneous

山口英世先生

Laboratory diagnosis of imported mycoses : how to safely execute laboratory examinations Hideyo YAMAGUCHI 5 1 6 1 1976 7 019-0395 359 Teikyo University Institute of Medical Mycology (TIMM) (359 Otsuka,

4) H. Takayama et al.: J. Med. Chem., 45, 1949 (2002). 5) H. Takayama et al.: J. Am. Chem. Soc., 112, 8635 (2000). 6) H. Takayama et al.: Tetrahedron Lett., 42, 2995 (2001). 9) M. Kitajima et al: Chem.

988 CHEMOTHERAPY NOV. 1971

988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical

2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1

200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3

ヒビスコール液A カタログ

1 2 3 2002 10 Centers for Disease Control and Prevention CDC A 1. 2. 0.2% 3. 1 A 2 3 4 5 6 7 1 1 1. 2. 3. 2 1. 1 0.2% 10 Pseudomonas aeruginosa ATCC 27853 20 20 Proteus vulgaris ATCC 13315 30 20 Escherichia

C/NC : committed/noncommitted

C/NC : committed/noncommitted 110 time post-icd implant 1) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report : Effect of encainaide and flecainide on mortality in a

CHEMOTHERAPY AUG. 1982 VOL. 30 NO. 8 CHEMOTHERAPY Fig.1 Relation between various-closis of cefazolin and detection rate of organisms in heart blood of dying mice with E. coli and P. aeruginosa infection

報告書 H22-2A-09

061-0293 1757 TEL 0133-23-1211 2.0% 0.5% in vitro QOL Quality of Life 1 MCE-400 400 mpa s Duck Algin 350M M/G 0.8 70 80 C 20% 50 C 1.0% 5 C SV-10 5 C 10 ml E TV 20H model E 1 34 R24 1 ml 5 C 30 6 12 30

1) van Meer, G., Op den Kamp, J. A.: J. Cell. Biochem., 19, 193-2040982) 2) Gaffet, P., Bettache, N., Bienvenue, A.: Biochemistry, 34, 6762-6769(1995) 3) Sims, P. J., Wiedmer, T.: Thromb. Haemost., 86,

No.5

untitled

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Int J Radiat Oncol Biol Phys 49 Cancer 101 Int J Radiat Oncol Biol Phys 60 Chest 124 Int J Radiat Oncol Biol Phys 56 Int J Radiat Oncol Biol Phys 49 Chest 124 Int J

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,

051

Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 389( 15 ) 1. MDS collagenase 2. 1 3. 4. / 390( 16 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 4 Aug. 4 4 2004 10 2 1 NTT Aug. THE JAPANESE JOURNAL OF ANTIBIOTICS

untitled

FK506 FK506 2005 17 4 1 1,2) 1 1943 18 12 1944 9 11 1946 4 2 11 J. W. 1948 26 2 1949 11 19511954 E-mail: [email protected] 2013 3 141 1956 4 1 10 1 1961 10 NRDC C CC CC CC CC CCNa 1962 7-7ACA

indd

Molecular Targeted Therapy for Lung Cancer from a Pharmaceutical Point of Viewe Naho SASAKI epidermal growth factor receptor tyrosine kinase inhibitor :EGFR-TKI vascular endothelial growth factor:vegf